{"id":"gemtuzumab-ozogamycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Hepatotoxicity (elevated transaminases)"},{"rate":null,"effect":"Veno-occlusive disease (VOD)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL1201506","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug binds to CD33, a myeloid antigen expressed on AML blasts, and undergoes internalization. Once inside the cell, the calicheamicin payload is released and causes DNA double-strand breaks, leading to apoptosis. This antibody-drug conjugate approach allows targeted delivery of cytotoxic chemotherapy to leukemic cells while sparing normal tissues.","oneSentence":"Gemtuzumab ozogamicin is a monoclonal antibody targeting CD33 on acute myeloid leukemia cells, delivering a cytotoxic calicheamicin payload directly to leukemic blasts.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:52.333Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML), newly diagnosed or relapsed/refractory"}]},"trialDetails":[{"nctId":"NCT00860639","phase":"PHASE3","title":"Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2007-10","conditions":"Acute Myeloid Leukemia","enrollment":327}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["gemtuzumab ozogamycin (MYLOTARG ®)"],"phase":"phase_3","status":"active","brandName":"gemtuzumab ozogamycin","genericName":"gemtuzumab ozogamycin","companyName":"Nantes University Hospital","companyId":"nantes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemtuzumab ozogamycin is a binding agent that targets the myeloid cell surface antigen CD33. It is used to treat Acute Myeloid Leukemia, specifically in patients with intermediate risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}